VLP tech recognized as top-10 medical innovation

The Cleveland Clinic has recognized Novavax's use of genetically engineered virus-like particles in new vaccines as one of the year's top 10 medical innovations at its annual innovation summit.

Novavax develops recombinant structures that essentially look like a virus but don't have the genetic material needed to make them dangerous. Because they look like virus particles to the immune system, the body mounts a potent response that can stop the actual virus in its tracks. And the company says its technology is far less expensive and will be far more efficient in production.

"VLPs represent a very promising approach to preventing the spread of influenza as we recently demonstrated with the announcement of favorable results in a Phase IIa human clinical trial of our VLP based pandemic influenza vaccine," said CEO Dr. Rahul Singhvi.

- read the report from Medical News Today

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.